Tatva chintan pharma Chem Limited has filed its quarterly compliance certificate for the quarter ended March 31, 2026, in accordance with SEBI regulatory requirements. The company submitted the mandatory documentation to stock exchanges and depositories on April 6, 2026.

Regulatory Compliance Filing

The compliance certificate was filed pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. Company Secretary and Compliance Officer Ishwar Nayi signed and submitted the documentation to relevant regulatory bodies.

Registrar Confirmation

MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, serves as the company's registrar and share transfer agent. The registrar issued the compliance certificate on April 3, 2026, confirming proper handling of dematerialisation processes during the quarter.

The registrar confirmed that securities received from depository participants for dematerialisation during the quarter ended March 31, 2026, were properly processed and confirmed to the depositories. All security certificates received for dematerialisation were verified, mutilated, and cancelled following due verification procedures.

Depository Operations

The compliance certificate covers the company's adherence to prescribed timelines for depository operations. Key confirmations include:

• Securities received for dematerialisation were accepted or rejected within regulatory timelines
• Security certificates comprised in dematerialisation requests have been listed on stock exchanges where existing securities are traded
• Names of depositories have been substituted in the register of members as registered owners
• All verification procedures were completed by depository participants as required

Regulatory Distribution

The compliance certificate was distributed to multiple regulatory bodies and stock exchanges. Recipients included BSE Limited, National Stock Exchange of India Limited, National Securities Depository Limited, and Central Depositories Services (India) Limited.

The company confirmed that the compliance information would be uploaded on its official website for public access, ensuring transparency in regulatory compliance matters.

Tatva chintan pharma Chem Limited has announced its upcoming investor engagement schedule, informing stock exchanges about a planned meeting with OysterRock Capital. The pharmaceutical company submitted this disclosure to BSE Limited and National Stock Exchange of India Limited on March 19, 2026, in compliance with regulatory requirements.

Meeting Details

The company has scheduled a virtual investor interaction with specific parameters outlined for transparency and regulatory compliance.

Regulatory Compliance and Information Sharing

Tatva Chintan Pharma Chem Limited has emphasized its commitment to maintaining regulatory standards during the investor interaction. The company has clearly stated that discussions will be limited to publicly available information only. No confidential or unpublished price sensitive information (UPSI) will be shared during the meeting, ensuring compliance with SEBI guidelines.

The company has also noted that the meeting schedule is subject to change if required. All relevant information regarding this investor interaction will be made available on the company's official website at www.tatvachintan.com for public access.

Corporate Communication

The disclosure was signed by Ishwar Nayi, Company Secretary and Compliance Officer, with membership number A37444. The communication was formally submitted to both major stock exchanges where the company is listed, maintaining transparency in corporate governance practices. This proactive disclosure demonstrates the company's adherence to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.